Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

Multiple Cancer Types

This is an open-label, multi-center, non-randomized, Phase 1b/2 study to assess the safety
and efficacy of fruquintinib in combination with tislelizumab in patients with locally
advanced or metastatic solid tumors. This study will be conducted in 2 parts; a Safety
Lead-in Phase (Part 1) and a Dose Expansion Phase (Part 2).

The Safety Lead-in Phase, open to any-comer solid tumors, will determine the RP2D. The RP2D
will be administered to 3 cohorts of patients in the Dose Expansion Phase.

- Cohort A: Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IO-treated)

- Cohort B: Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IO-Nave)

- Cohort C: Advanced or Metastatic Endometrial Cancer (EC) (IO-Nave)

- Cohort D: Advanced or Metastatic Colorectal Cancer (mCRC) (IO-Nave)
Miscellaneous, Phase I
Eng, Cathy

Sparing Bone Marrow in Patients with Stage III-IV Lung Cancer, VMAT Trial


This phase II trial tests whether designing radiation to avoid bone marrow in the spine (vertebral bone marrow) leads to less reduction of white blood cell counts (lymphopenia) in patients with lung cancer. This sparing technique could lead to better disease control and outcome.
Osmundson, Evan

Metabolism Informed Smoking Treatment for Smoking Cessation in Medicaid and Medicare Patients


This phase III trial compares the effect of a metabolism informed smoking treatment (MIST) to standard therapy to help Medicaid and Medicare patients quit smoking. Quitting smoking can help prevent smoking-related diseases like cancer and heart disease and can help patients live longer. MIST includes a free screening blood test to show how fast the body breaks down nicotine in order to help people quit smoking. The screening test is the first step to a study that may help doctors choose the best medication to quit smoking.
Tindle, Hilary

Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)


This phase II trial tests whether atezolizumab and bevacizumab after Y-90 TARE works to shrink tumors in patients with hepatocellular (liver) cancer that cannot be removed by surgery (unresectable). Transarterial radioembolization is a minimally invasive procedure that combines embolization and radiation therapy to treat liver cancer. Tiny glass or resin beads filled with the radioactive isotope yttrium Y-90 are placed inside the blood vessels that feed the tumor. This blocks the supply of blood to the cancer cells and delivers a high dose of radiation to the tumor while sparing normal tissue. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Bevacizumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Adding atezolizumab and bevacizumab after Y90 TARE may prevent liver cancer from returning for a longer period.
Goff, Laura

Hypofractionated Radiotherapy Followed by Immediate Surgery for the Treatment of Soft Tissue Sarcomas


This phase II trial studies the effect of hypofractionated radiotherapy followed by immediate surgery in treating patients with soft tissue sarcoma. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Giving hypofractionated radiotherapy followed by immediate surgery may allow patients with sarcomas to be treated in a much more rapid and convenient fashion.
Shinohara, Eric

Active Myeloid Target Compound Decitabine and Cedazuridine in Combination with Itacitinib for the Treatment of Myelodysplastic/Myeloproliferative Neoplasm (MDS/MPN) Overlap Syndromes, ABNL-MARRO Study

Multiple Cancer Types

This phase I/II trial tests the safety, side effects, and best dose of decitabine and cedazuridine (ASTX727) in combination with itacitinib and how well they work in treating patients with myelodysplastic/ myeloproliferative neoplasm. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Itacitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving decitabine and cedazuridine in combination with itacitinib may work better in treating patients with myelodysplastic/myeloproliferative neoplasm.
Hematologic, Myelodysplastic Syndrome
Savona, Michael

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma

Multiple Cancer Types

The purpose of this study is to assess the safety, tolerability, drug levels, and preliminary
efficacy of relatlimab plus nivolumab in pediatric and young adult participants with
recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma.
Lymphoma, Pediatrics
Friedman, Debra

Gabapentin plus Ketamine for the Prevention of Acute and Chronic Pain in Patients with Locally Advanced Head and Neck Cancer Undergoing Chemoradiation

Multiple Cancer Types

This phase I/II trial studies the side effects and best dose of a combination of gabapentin and ketamine and to see how well it works to prevent acute and chronic pain in patients receiving chemotherapy and radiation therapy (chemoradiation) for head and neck cancer that has spread to nearby tissue or lymph nodes (locally advanced). Gabapentin is a medication that is commonly used to treat nerve related pain. Specifically, it has been used to treat pain involving the mouth, throat and nasal passages in head and neck cancer patients treated with radiation. Ketamine is a type of general anesthetic that blocks pathways to the brain involved with sensing pain. This trial may help doctors determine how patients tolerate the combination of gabapentin and ketamine and to find the correct dosing for ketamine in those taking gabapentin. This will be the basis for a future, larger study to look at how effective this combination is at reducing and/or preventing pain in head and neck cancer patients.
Head/Neck, Phase I
Lockney, Natalie

To learn more about any of our clinical
trials, call 615-936-8422.